tag respiratory 
Rethinking Clinical Trials
NOVEMBER 21, 2022
Sick children, when they are acutely ill, start with standard oxygen therapy, which escalates to noninvasive respiratory support (CPAP/BIPAP or high flow nasal cannula) before invasive ventilation support in the ICU. pctGR, @Collaboratory1.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. —- End —-.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.
Rethinking Clinical Trials
MAY 5, 2023
For the intervention, respiratory therapists titrated FiO2 to achieve SpO2 beginning within 15 minutes of initiation of mechanical ventilation and ending at discontinuation from mechanical ventilation or transfer. There was a washout period the last 7 days of each two-month period. The trial was conducted under waiver of informed consent.
The Pharma Data
DECEMBER 3, 2020
Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag © Technology. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
pharmaphorum
JUNE 2, 2021
million price tag make it is the most expensive treatment ever approved for NHS funding, as it provides “exceptional benefit” to babies with the disease. Spinraza was also rejected by NICE in the first instance, but was eventually recommended for SMA types 1, 2 and 3 after a confidential price discount from Biogen.
Expert insights. Personalized for you.
130 
Let's personalize your content